Compare Prudential PLC (PUK) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Prudential PLC vs Sanofi SA — how do they compare? Prudential PLC trades at $29.47 (market cap $35.71B), while Sanofi SA trades at $43.89 (market cap $104.85B). The key difference: Sanofi SA is far larger — about 2.9× Prudential PLC's market cap, and Sanofi SA pays the higher dividend (5.53%). Which is the better fit depends on your goals.
| PUK | SNY | |
|---|---|---|
Market Cap | $35.71B | $104.85B |
Sector | Financials | Health |
52-Week High | $33.61 | $52.34 |
52-Week Low | $24.80 | $41.33 |
Enterprise Value | $37.15B | $121.38B |
Dividend Yield | 1.84% | 5.53% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Prudential (PUK) trades at $28.88, up 2.09% today, showing strong fundamental momentum with revenue growth from $16.21B in 2024 to $27.4B projected for 2025 and consistent earnings beats. The stock appears undervalued with a P/E of 9.21 and P/S of 1.34, while technical indicators show a bearish trend despite neutral oscillators. Recent news highlights JP Morgan's positive catalyst watch ahead of August earnings and strategic moves in Asian markets.
The outlook remains positive given strong profitability (21.15% ROE) and analyst support (50% buy ratings), but risks include regulatory challenges in Japan and China exposure. Current valuation metrics suggest potential upside if earnings momentum continues, though technical resistance near $29 may limit near-term gains.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Prudential PLC
Prudential is an Asia and Africa health and life insurance business and is focused on long-term savings. The business is increasingly focusing on digital offerings and creating strong brand equity and relationships with customers of its products through these.
Read more on PUK →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
